WallStSmart

Fresenius Medical Care Corporation (FMS)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 1230% more annual revenue ($19.36B vs $1.46B). FMS leads profitability with a 4.9% profit margin vs 3.6%. FMS trades at a lower P/E of 11.9x. GRDN earns a higher WallStSmart Score of 50/100 (D+).

FMS

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96

GRDN

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 6.5Value: 4.0Quality: 7.0
Piotroski: 3/9Altman Z: 5.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+69.0%)

Margin of Safety

+69.0%

Fair Value

$77.65

Current Price

$22.03

$55.62 discount

UndervaluedFair: $77.65Overvalued

Intrinsic value data unavailable for GRDN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.9x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.798/10

Growing faster than its price suggests

GRDN4 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
5.3010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
39.0%8/10

Earnings expanding 39.0% YoY

Areas to Watch

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.1%3/10

ROE of 7.1% — below average capital efficiency

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

Revenue GrowthGrowth
-5.5%2/10

Revenue declined 5.5%

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.79 suggests the stock is reasonably priced for its growth.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 4.9% margins leave little buffer for downturns.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 51.3x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

GRDN is growing revenue faster at 2.2% — sustainability is the question.

FMS generates stronger free cash flow (37M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (50/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, serving assisted living and skilled nursing facilities. The company is recognized for its commitment to personalized medication management, high standards of quality and compliance, and superior customer service. By utilizing advanced technology and deep pharmaceutical expertise, Guardian not only improves patient outcomes but also streamlines operations for healthcare partners. With a substantial operational presence in multiple states, Guardian is well-equipped to address the growing demand for tailored pharmacy services in a rapidly evolving healthcare environment.

Want to dig deeper into these stocks?